Search research articles
Contact Us
Filters
Showing results (1-10 of 49) with videos related to
Page
of 5
Sort By:
Quality & Safety in Health Care
|
February 11, 2009
Development of the pharmacy safety climate questionnaire: a principal components analysis
D M Ashcroft, D Parker
Journal of Clinical Pharmacy and Therapeutics
|
December 21, 2006
Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials
L-C Chen, D M Ashcroft
Pharmacoeconomics
|
January 6, 2000
Herbal remedies: issues in licensing and economic evaluation
D M Ashcroft, A L Po
Journal of Clinical Pharmacy and Therapeutics
|
May 22, 2004
Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control
L-C Chen, R A Elliott, D M Ashcroft
The British Journal of Dermatology
|
November 17, 2006
Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists
D M Ashcroft, E Seston, C E M Griffiths
Journal of Clinical Pharmacy and Therapeutics
|
May 11, 2007
Influence of prescription charges on repeat prescribing in primary care
F Bradley, R Elvey, D M Ashcroft, et al.
Quality & Safety in Health Care
|
February 4, 2006
Likelihood of reporting adverse events in community pharmacy: an experimental study
D M Ashcroft, C Morecroft, D Parker, et al.
Journal of Clinical Pharmacy and Therapeutics
|
April 20, 2000
Therapeutic strategies for psoriasis
D M Ashcroft, A Li Wan Po, C E Griffiths
Quality & Safety in Health Care
|
December 6, 2005
Safety culture assessment in community pharmacy: development, face validity, and feasibility of the Manchester Patient Safety Assessment Framework
D M Ashcroft, C Morecroft, D Parker, et al.
The Cochrane Database of Systematic Reviews
|
January 27, 2006
Interventions for vitiligo
M E Whitton, D M Ashcroft, C W Barrett, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 49) with videos related to
Sort By:
Page
of 5
Quality & Safety in Health Care
|
February 11, 2009
Development of the pharmacy safety climate questionnaire: a principal components analysis
D M Ashcroft, D Parker
Journal of Clinical Pharmacy and Therapeutics
|
December 21, 2006
Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials
L-C Chen, D M Ashcroft
Pharmacoeconomics
|
January 6, 2000
Herbal remedies: issues in licensing and economic evaluation
D M Ashcroft, A L Po
Journal of Clinical Pharmacy and Therapeutics
|
May 22, 2004
Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control
L-C Chen, R A Elliott, D M Ashcroft
The British Journal of Dermatology
|
November 17, 2006
Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists
D M Ashcroft, E Seston, C E M Griffiths
Journal of Clinical Pharmacy and Therapeutics
|
May 11, 2007
Influence of prescription charges on repeat prescribing in primary care
F Bradley, R Elvey, D M Ashcroft, et al.
Quality & Safety in Health Care
|
February 4, 2006
Likelihood of reporting adverse events in community pharmacy: an experimental study
D M Ashcroft, C Morecroft, D Parker, et al.
Journal of Clinical Pharmacy and Therapeutics
|
April 20, 2000
Therapeutic strategies for psoriasis
D M Ashcroft, A Li Wan Po, C E Griffiths
Quality & Safety in Health Care
|
December 6, 2005
Safety culture assessment in community pharmacy: development, face validity, and feasibility of the Manchester Patient Safety Assessment Framework
D M Ashcroft, C Morecroft, D Parker, et al.
The Cochrane Database of Systematic Reviews
|
January 27, 2006
Interventions for vitiligo
M E Whitton, D M Ashcroft, C W Barrett, et al.
Page
of 5